Actelion Pharmaceuticals Ltd : Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland

     Actelion Pharmaceuticals Ltd : Actelion's Annual General Meeting of
                   Shareholders held in Basel, Switzerland

Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of
Shareholders held in Basel, Switzerland . Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this

ALLSCHWIL/BASEL, SWITZERLAND  - 18  April  2013 -  At today's  Annual  General 
Meeting of Actelion Ltd (SIX:  ATLN), held in Basel Switzerland,  shareholders 
voted on a number of resolutions put forward by the Company's Board.

The meeting was attended by 272 shareholders. A total of 60'550'649 shares  or 
47.76% of the total outstanding shares were represented.

Lead by the Chairman of the Board, Jean-Pierre Garnier, the company  presented 
a review of the  company's 2012 performance.  Highlights included the  ongoing 
demand for  Actelion's medicines,  the success  in key  clinical studies,  the 
strategic refocusing on specialty pharmaceuticals  and the continuation of  an 
800 million share buyback program. The chairman reminded the shareholders that
Actelion created significant value in the year under review and was among  the 
top performers in the 2012 Blue Chip Index SMI at the Swiss Stock Market.

The shareholders approved the Business Report consisting of the Annual Report,
the Annual Statutory Accounts and the Consolidated Accounts for the year 2012.

A proposal  by  the  Board  to appropriate  available  earnings  from  capital 
contribution and  distribute as  a dividend  in  the amount  of CHF  1.00  per 
registered share was passed by shareholders.

Shareholders did  not vote  favorably in  the consultative  vote on  the  2012 
compensation report, with  60.24 percent  against. The Chairman  of the  Board 
expressed his confidence that - based on the changes already made for 2013 and
through ongoing consultation with shareholders - a remuneration system will be
put in place that will find the  approval of the company's owners at the  next 

The shareholders granted discharge  to all members of  the Board of  Directors 
and of the Senior Management.

A proposal by the Board to reduce share capital by cancellation of repurchased
shares was passed by the shareholders.

Actelion's shareholders re-elected Mr. Werner  Henrich, Mr. Armin Kessler  and 
Mr. Jean Malo to the Board for a term of three years.

In addition, the shareholders elected a new director, Mr. John J. Greisch,  to 
the Board for a term of three years.

Following the  AGM, Actelion's  Board  comprises a  total of  eleven  members: 
Jean-Pierre Garnier (Chairman),  Juhani Anttila,  Robert Bertolini,  Jean-Paul 
Clozel, Carl Feldbaum, John J.  Greisch, Peter Gruss, Werner Henrich,  Michael 
Jacobi, Armin Kessler and Jean Malo.

Finally, the shareholders confirmed Ernst  & Young as the Company's  statutory 
auditors for the business year 2013.




Mr. John J. Greisch is currently  President (as Executive Director) and  Chief 
Executive Officer of Hill-Rom  Holdings, Inc., a  leading medical supplier  of 
patient support  systems  such  as hospital  beds,  therapeutic  surfaces  and 
stretchers. Under Mr. Greisch's leadership, Hill-Rom increased its investments
in research  and development,  introducing new  smart bed  technology and  new 
surfaces to the market as  well as expanding its Singapore-based  Asia-Pacific 
Innovation Center.

Before  joining   Hill-Rom,  Mr.   Greisch  spent   seven  years   at   Baxter 
International, Inc.  in  various  executive positions  in  corporate  finance, 
operations  and  general  management.  From  2004-2006,  he  served  as  Chief 
Financial Officer and from 2006-2009 as President International Operations.

Mr Greisch  earned a  Bachelor's degree  in Business  Administration from  the 
Miami University, US and a Master's Degree in Management (MBA equivalent) from
the Northwestern University in Illinois, US

Mr. Greisch also serves on the  Board of Lurie Children's Hospital in  Chicago 
and is  a  past  member  of  the Business  School  Advisory  Board  for  Miami 
University's Farmer School of Business.


Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland.  Actelion's  first drug  Tracleer®,  an  orally 
available dual endothelin receptor antagonist, has been approved as a  therapy 
for pulmonary arterial hypertension.  Actelion markets Tracleer® through  its 
own subsidiaries in key markets worldwide, including the United States  (based 
in South  San Francisco),  the European  Union, Japan,  Canada, Australia  and 

Founded in  late 1997  Actelion  is a  leading  player in  innovative  science 
related to the endothelium - the single layer of cells separating every  blood 
vessel from the blood  stream. Actelion's over 2,400  employees focus on  the 
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares  are traded on the  SIX Swiss Exchange  (ticker 
symbol: ATLN) as  part of the  Swiss blue-chip index  SMI (Swiss Market  Index 

For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36

Press Release PDF


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;
Press spacebar to pause and continue. Press esc to stop.